However, it remains to be demonstrated whether the therapeutic effect of HDAC6 inhibition is only relevant for patients with a mutation in HSPB1, or whether it can be extrapolated to other forms of CMT2, or even to CMT1. This evidence concerns the gene HSPB1 and Charcot-Marie-Tooth disease type 1.